Wegovy in Australia: the complete guide

What is Wegovy?

Wegovy is the brand name for semaglutide at a 2.4mg weekly dose, manufactured by Danish pharmaceutical company Novo Nordisk. It belongs to a class of medications called GLP-1 receptor agonists — drugs that mimic a natural gut hormone involved in appetite regulation, blood sugar control, and gastric emptying.

The TGA approved Wegovy in Australia in August 2024 for three indications:

• Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• Chronic weight management in adolescents aged 12 and over with obesity
• Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight

Wegovy contains the same active ingredient as Ozempic, but at a higher dose and with a different approval. Ozempic (semaglutide up to 1mg) is approved for type 2 diabetes management, not weight loss. Since October 2024, new off-label prescriptions of Ozempic for weight loss have been restricted in Australia.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled, disposable pen. You don't need to visit a clinic for injections — patients self-administer at home after initial guidance from their doctor.

How does Wegovy work?

After you eat, your gut naturally releases a hormone called GLP-1 (glucagon-like peptide-1). This hormone signals to your brain that you're full, slows the rate at which food leaves your stomach, and helps regulate blood sugar levels. In people with obesity, these natural signals may be less effective.

Semaglutide (the active ingredient in Wegovy) is a synthetic version of GLP-1 that's been modified to last much longer in the body — about 7 days versus minutes for the natural hormone. This allows once-weekly dosing and sustained effects on appetite.

Wegovy acts on multiple pathways simultaneously:

• Appetite centres in the brain (hypothalamus): Reduces hunger signals and increases feelings of satiety. Many patients describe this as "food noise" — the constant background thinking about food — disappearing.
• Gastric emptying: Slows the rate at which food moves from the stomach into the intestines, meaning you feel fuller for longer after eating.
• Reward pathways: Reduces the rewarding properties of highly palatable foods. Patients often report reduced cravings for sweet, fatty, and processed foods.
• Blood sugar regulation: Increases insulin secretion when blood sugar is elevated and reduces glucagon, improving overall metabolic health.

The combined effect is that you eat less naturally — not through willpower or forced restriction, but because your body's appetite signals are recalibrated. Most patients report eating 20–30% fewer calories without consciously dieting.

Who is eligible for Wegovy in Australia?

Under TGA guidelines, Wegovy is indicated for adults who meet one of these criteria:

• BMI ≥30 kg/m² (obesity) — eligible regardless of comorbidities
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity: type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, PCOS, or cardiovascular disease

Not sure of your BMI? Use our calculator.

For the pending PBS listing, the criteria are narrower:

• BMI ≥35 (or ≥32.5 for Asian, Aboriginal, and Torres Strait Islander populations)
• AND established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral arterial disease)

Wegovy is not suitable for people with:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Pregnancy or breastfeeding (stop at least 2 months before planned conception)
• Severe gastrointestinal disease

Your doctor will also check for interactions with existing medications, particularly insulin and sulfonylureas (risk of hypoglycaemia).

Check your eligibility →

Expected weight loss results

Wegovy's clinical evidence comes from the STEP programme — one of the largest obesity medication trial programmes ever conducted, involving over 15,000 participants across multiple studies.

STEP 1 (the main weight loss trial)

• 1,961 adults with BMI ≥30 (or ≥27 with comorbidity), without diabetes
• Average weight loss: 14.9% of body weight over 68 weeks
• Placebo group lost 2.4% — so the medication-attributable loss was approximately 12.5%
• One-third of participants lost 20% or more of their body weight
• 86% lost at least 5%, and 69% lost at least 10%

SELECT trial (cardiovascular outcomes)

• 17,604 adults with established cardiovascular disease and BMI ≥27
• 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death)
• Average weight loss of 9.4% over 4 years of treatment
• This was the first weight loss medication to demonstrate direct cardiovascular benefits

What this means in practice

For someone weighing 100kg, average weight loss would be approximately 15kg over 15-16 months. However, individual results vary enormously — some patients lose 25%+ while others lose less than 5%. Factors that influence your response include genetics, starting weight, diet quality, physical activity, medication adherence, and dose tolerance.

Weight loss typically follows this pattern:

• Months 1–2: Gradual start during dose escalation. 1–3% body weight loss.
• Months 3–6: Most rapid weight loss phase. 5–10% total by month 6.
• Months 6–12: Continued loss but slowing. 10–15% total.
• Months 12–18: Weight stabilises at maximum loss for most patients.

Important: weight is commonly regained after stopping Wegovy. The medication counteracts biological weight-defence mechanisms — when removed, those mechanisms resume. Wegovy is designed as a long-term treatment, similar to blood pressure medication.

Dosage and dose escalation schedule

Wegovy uses a gradual dose escalation over 16 weeks to minimise gastrointestinal side effects. You start low and increase monthly:

If you experience significant side effects during escalation, your doctor may extend the time at a given dose before increasing — for example, staying at 1.0mg for 8 weeks instead of 4 before moving to 1.7mg. The goal is to reach the therapeutic dose with manageable side effects.

The injection can be given at any time of day, with or without food. Most people choose a consistent day and time each week — many set a phone reminder.

Step-by-step injection guide →

Side effects

The most common side effects are gastrointestinal, particularly during dose escalation. They typically improve as your body adjusts:

Serious but rare side effects:

• Pancreatitis: Sudden severe abdominal pain radiating to the back. Stop medication and seek immediate medical attention.
• Gallbladder problems: Risk increases with rapid weight loss. Report upper-right abdominal pain to your doctor.
• Thyroid concerns: Animal studies showed thyroid tumour risk; not confirmed in humans but monitored. Contraindicated in people with MTC history.
• Suicidal ideation: The TGA and FDA are monitoring reports. No causal link established but discuss any mood changes with your doctor.

Detailed week-by-week side effects guide →

Cost in Australia

As of 2026-04-03, Wegovy is only available on private prescription for weight management. Monthly costs at the maintenance dose (2.4mg):

Prices last checked 2026-04-03. Costs during escalation phase are lower.

Total first-year cost estimate: $3,800–$5,200 (including lower-cost escalation phase).

Annual maintenance cost: $4,800–$5,500/year at full dose.

If PBS listed, eligible patients would pay approximately $31.60/script ($7.70 concession).

Full cost breakdown with provider comparison →

PBS status

In January 2026, the PBAC recommended Wegovy for PBS listing for a specific patient group:

• Adults with BMI ≥35 (≥32.5 for Asian, Aboriginal, Torres Strait Islander populations)
• AND established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral arterial disease)

Price negotiations between the government and Novo Nordisk are underway. There is no confirmed date for when Wegovy will appear on the PBS.

This means most people using Wegovy for weight management alone would not qualify for PBS pricing initially. The criteria may broaden over time, but the estimated cost to the government of wider subsidisation is over $1 billion annually.

Full PBS guide →

How to get Wegovy in Australia

Option 1: Through your GP

Book an appointment with your regular doctor. They'll assess your BMI, health conditions, and suitability for Wegovy. If eligible, they'll write a private prescription that you fill at a pharmacy. Pros: continuity of care, full physical examination. Cons: wait times, not all GPs are experienced with GLP-1 prescribing.

Option 2: Through a telehealth provider

Multiple online clinics now prescribe Wegovy via phone or video consultation with AHPRA-registered doctors. The process is typically: complete an online health assessment → book a consultation → doctor assesses eligibility → prescription issued → medication delivered to your door or e-script sent.

This is often faster than GP appointments and some providers include delivery in their pricing.

Best telehealth providers for Wegovy →

Detailed step-by-step guide →

Wegovy vs alternatives

Frequently asked questions